The retina in X-linked retinoschisis does not tear so much as split. A faulty gene called RS1 leaves the tissue unable to hold itself together, and tiny fluid-filled cavities pry the central retina apart from the inside. Boys are affected almost exclusively, and their central vision fades as the macula pulls open. There has been no treatment that fixes the underlying problem. A trial published in The New England Journal of Medicine on June 11 tested whether a single injection carrying a healthy copy of the gene could change that.
The answer, at least at one year, was cautiously yes. Twelve patients between 5 and 18 years old each received one subretinal injection of scAAV8-hRS1 into a single eye. That name unpacks into a delivery system: an adeno-associated virus, serotype 8, carrying human RS1 complementary DNA, placed directly under the retina by a surgeon. The other eye went untreated and served as a within-person comparison. The point of a phase-1 trial is safety first, and the researchers watched for problems across 52 weeks.
What the eye looked like afterward
The most concrete result came from imaging. Swept-source optical coherence tomography, which slices a cross-section through the living retina, showed that the schisis cavity had closed in the treated eye of all 12 patients by week 13. Central retinal thickness in treated eyes dropped by an average of 437.7 micrometers as the fluid pockets collapsed. In the untreated eyes the same measure barely moved, falling 17.2 micrometers. In 9 of the 12 patients, the outer retinal layers had knitted back into a continuous sheet by week 52.
Vision followed, though more modestly. Best corrected visual acuity in treated eyes improved by an average of 10.8 letters on the standard chart. Untreated eyes gained 2.4 letters over the same span. Ten letters is roughly two lines, which is the kind of change a person tends to notice.
The safety ledger
Across the year, 56 adverse events were logged. None reached grade 3 or higher, and no patient developed ocular inflammation, which is a recurring worry with viral vectors delivered to the eye. One patient developed a macular hole in the treated eye at week 1, an event tied to the surgery itself rather than the gene. Two dose levels were tested, three patients each in the initial cohorts, with three more added to each in an expansion phase. Both doses were tolerated.
What is worth noting is where the improvement did not show up. Full-field electroretinography, which measures the electrical response of photoreceptors and the bipolar cells that pass their signal along, did not show a clinically meaningful change in the treated eyes. Neither did microperimetry, a test of how sensitive the macula is to spots of light. So the structural repair was clear and the acuity ticked up, but the deeper functional readouts of the light-sensing machinery stayed roughly flat over the year.
How much to read into it
This is a small, early study. Twelve people, one year, no randomization beyond the untreated fellow eye, run at centers in China and registered with the Chinese Clinical Trial Registry. The gap between a closed cavity on a scan and durable, lived vision is exactly the thing longer follow-up is meant to test. It is also unclear whether the acuity gain will hold, grow, or fade, and whether the flat electroretinography signal matters more than the imaging suggests. The authors write plainly that further clinical testing is warranted, which is the honest read.
Still, the disease has been a hard target. Retinoschisin, the protein RS1 encodes, is secreted and thought to act as a kind of glue binding retinal layers, so replacing the gene has long been the obvious strategy and repeatedly difficult to land in patients. Seeing the split retina physically reappose in every treated eye, on a virus delivered in one shot, is the sort of result that earns a next trial.
Comments